The big pharma’s cystic fibrosis deal with Galapagos is greeted with surprise, but the gamble might actually make sense.
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…
Extending a pulmonary hypertension drug’s lifecycle could help battle generic erosion, but investors might have been looking for a more transformative deal.
The win Restorbio is claiming in a mid-stage study is by no means clear-cut.
Galapagos contemplates life without Abbvie as Pelican trial results disappoint.
Mid-stage data for Tocagen and Restorbio are approaching.
Competitive bidding, an attempt to bring down Medicare costs, might lead to higher out-of-pocket costs for patients.